Blog Header

In: oncostellae

February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis
febrero 21, 2020

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More
11 October 2019
IO4COLON project progress

febrero 21, 2020

Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos en tratamiento de cáncer de colon. El pasado viernes (11 de octubre…

Read More
May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing
febrero 20, 2020

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More
10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

marzo 24, 2019

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More
22 Feb 2019
IO4COLON Project Presentation

febrero 23, 2019

Last 22th of February at 12:00 pm was celebrated the Presentation of IO4COLON Project in the CIQUS Research Center We are pleased…

Read More
25-27 Sep 2018
Oncostellae participates at Biospain 2018 in Seville

julio 19, 2018

Oncostellae participates at the 2018 Biospain congress that takes place from 25th to 27th of September  2018  in the Fibes Exhibition &…

Read More
14 Feb 2017
Cuatro biotecnológicas gallegas se alían en una plataforma para buscar nuevos fármacos contra el cáncer
febrero 14, 2016

GalChimia, AMSLab, Oncostellae y Nanogap presentan Neogalfarma, que aspira a diseñar, sintetizar y evaluar biológicamente nuevas moléculas antitumorales Cuatro empresas gallegas…

Read More